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Alzheimer’s disease (AD), the most common type of dementia among older people, is characterized by the accumulation of
β-amyloid (Aβ) senile plaques and neurofibrillary tangles composed of hyperphosphorylated tau in the brain. Despite major
advances in understanding the molecular etiology of the disease, progress in the clinical treatment of AD patients has been
extremely limited. Therefore, new and more eﬀective therapeutic approaches are needed. Accumulating evidence from human
and animal studies suggests that the long-term consumption of caﬀeine, the most commonly used psychoactive drug in the world,
may be protective against AD. The mechanisms underlying the suggested beneficial eﬀect of caﬀeine against AD remain to be
elucidated. In recent studies, several potential neuroprotective eﬀects of caﬀeine have been proposed. Interestingly, a recent study
in rats showed that the long-term consumption of caﬀeine increased cerebrospinal fluid (CSF) production, associated with the
increased expression of Na+-K+ ATPase and increased cerebral blood flow. Compromised function of the choroid plexus and
defective CSF production and turnover, with diminished clearance of Aβ, may be one mechanism implicated in the pathogenesis
of late-onset AD. If reduced CSF turnover is a risk factor for AD, then therapeutic strategies to improve CSF flow are reasonable.
In this paper, we hypothesize that long-term caﬀeine consumption could exert protective eﬀects against AD at least in part by
facilitating CSF production, turnover, and clearance. Further, we propose a preclinical experimental design allowing evaluation of
this hypothesis.
1. Introduction
Alzheimer’s disease (AD), the most common type of demen-
tia among older people, is a progressive neurodegenerative
disorder characterized clinically by a gradual decline in cog-
nition and daily functioning and behavioural alterations [1].
Principal neuropathological hallmarks of AD include extra-
cellular senile plaques containing β-amyloid (Aβ) derived
from β-amyloid precursor protein (APP) after sequential
cleavage by β-secretase and γ-secretase, and intracellular
neurofibrillary tangles caused by abnormally phosphorylated
tau protein [1]. Early-onset familial AD caused by mutations
in the genes encoding APP and the γ-secretase-complex
components presenilin-1 and presenilin-2 accounts for less
than 5% of the total number of AD cases [2]. The discov-
ery of pathogenic mutations in these three genes in rare
patients with autosomal dominant, early-onset AD provided
incontestable evidence that aberrant APP processing can be
suﬃcient to trigger the pathological cascade leading to AD
[3]. The pathological accumulation of Aβ in the far more
common late-onset AD is more likely to be the result of
defects in the clearance of Aβ [3]. Despite major advances in
understanding the molecular etiology of the disease, progress
in the clinical treatment of AD patients has been extremely
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limited. Therefore, new and more eﬀective therapeutic
approaches are needed. Accumulating evidence from human
and animal studies suggests that the long-term consumption
of caﬀeine, the most commonly used psychoactive drug in
the world, may be protective against AD [4–7]. Epidemio-
logically, a small case-control study showed that caﬀeine
intake was significantly inversely associated with AD [6]. A
prospective study also showed that daily coﬀee drinking was
associated with a reduced risk of AD after 5-year follow-up
[7]. There is also substantial evidence for a beneficial role
of caﬀeine in animal models of AD [4, 5]. The mechanisms
underlying the suggested protective eﬀect of caﬀeine against
AD remain to be elucidated. In this paper, we present a
hypothesis which speculates that long-term caﬀeine con-
sumption could exert protective eﬀects against AD at least
in part by facilitating cerebrospinal fluid (CSF) production,
turnover, and clearance. Further, we propose a preclinical
experimental design allowing evaluation of this hypothesis.
2. Presentation of the Hypothesis
There is evidence that production and turnover of CSF help
to clear toxic molecules such as Aβ from the interstitial-fluid
space of the brain to the bloodstream [8]. CSF production
and turnover have been shown to be decreased in ageing,
normal pressure hydrocephalus (NPH), and AD [8]. Using
the Masserman technique, Silverberg et al. [9] measured
a 50% decrease in CSF production among AD patients
when compared with Parkinson’s disease controls. Mean CSF
production in AD was 0.20 ± 0.06mL/min, and in controls
was 0.42 ± 0.13mL/min [8]. The authors calculated a
threefold decrease in CSF turnover in AD [8]. Age-associated
reduction in CSF production, with diminished clearance of
Aβ, may be a key factor in the onset and progression of AD
[8] and may be a particularly important mechanism of amy-
loid toxicity in late-onset AD cases in whom overproduction
of Aβmay not be operative [10].
There is some scientific rationale for considering AD, at
least in part, to be a choroid plexus (CP) disease, in that
reduced CSF production and turnover may contribute to the
diﬃculty in clearing Aβ from the aging brain [11]. CSF
is produced mainly by the four choroid plexuses that are
found one in each ventricle of the brain [12]. The CPs are
highly vascularized villous structures covered by a single
layer of epithelial cells [13, 14]. CPs have multiple func-
tions of synthesis, secretion, active transport, and selective
reabsorption of deleterious substances [13]. In young adults,
CSF is completely renewed six times a day [11]. Structural
changes in the CP coincide with diminished CSF production
in ageing, AD, and NPH [8]. In AD, choroid plexuses present
similar, although much more pronounced, abnormalities
than those observed in ageing [13, 14]. The CP in AD shows
epithelial atrophy, basement membrane thickening, cyst
formation, lipid accumulation, fibrosis, calcification, and
hyalinization and amyloid deposition in choroidal blood
vessels [8].
A review by Brown et al. [12] highlighted the molecular
mechanisms of CSF production. The epithelial cells of the CP
secrete CSF, by a process that involves the transport of Na+,
Cl− and HCO3− from the blood to the ventricles of the brain
[12]. This creates an osmotic gradient that is accompanied by
the secretion of H2O [12]. The movement of ions across the
cellular membrane is mediated by specific transporters and
ion channels that are distributed unequally on the basolateral
and apical sides of the CP epithelial layer [12]. Na+-K+
ATPase, K+ channels, and Na+-K+-2Cl− cotransporters are
expressed in the apical membrane [12]. By contrast the
basolateral membrane contains Cl−-HCO3− exchangers, a
variety of Na+-coupled HCO3
− transporters and K+-Cl−
cotransporters [12]. Aquaporin 1 (AQP1) mediates water
transport at the apical membrane, but the route across the
basolateral membrane is unknown [12].
Among the numerous proteins involved in choroidal
CSF production, it is known that Na+-K+ ATPase plays an
important role in CSF secretion [15]. The Na+-K+ ATPase is
a ubiquitous protein which catalyses 1 molecule of ATP to
exchange 3Na+ ions for 2K+ ions across the cell membrane
[16]. In the choroid plexus, this enzyme is located in the
luminal surface and provides the driving force for CSF
production [15]. Inhibitors of the Na+-K+ ATPase pump, for
example, the cardiac glycoside ouabain, have been shown
to reduce CSF production and the movement of Na+ into
the CSF [12]. Moreover, it has been shown that ageing
aﬀects choroidal proteins involved in CSF production [17].
Masseguin et al. [17] compared choroid plexuses of Sprague-
Dawley rats aged 10 or 20 months with those of 3-month-
old ones. Progressive and age-related changes in the Na+-K+
ATPase, carbonic anhydrase II and AQP1 expressions at the
apical and/or cytoplasmic level, as suggested by both the
decreases in the intensities of immunocytochemical and in
situ hybridization signals, indicated that ageing decreases
notably the protein expression of the enzymes and trans-
porters known to regulate the CSF production in choroid
plexus [17]. As noted above, with age, CSF production
decreases and could increase the risk for development of late-
onset AD [8].
In a recent study in young adult Sprague-Dawley rats,
Han et al. [15] found that the long-term consumption
of caﬀeine, a nonselective adenosine A1 and A2A receptor
antagonist, increased CSF production, associated with the in-
creased expression of Na+-K+ ATPase and increased cerebral
blood flow. Caﬀeine (0.3 or 0.6 g/L) was added to the
drinking water for 3 weeks in this study [15]. This low dose
of caﬀeine (0.3 g/L) has been shown to be representative of
the standard daily human consumption [15]. The authors
found a significant increase in the production of CSF in the
caﬀeine-treated rats compared to the control rats (5.02 ±
0.15 versus 2.95 ± 0.12 μL/min, P < .01) [15]. By contrast,
acute treatment with caﬀeine decreased the production of
CSF [15]. The rats treated with caﬀeine just once, before
measurement, showed a significantly reduced production of
CSF, by 22.3% compared to the control rats [15]. The “eﬀect
inversion” of caﬀeine was mediated by increased expression
of the A1 adenosine receptor, in the choroid plexus of rats
chronically treated with caﬀeine [15]. In accordance with
previous results showing increased expression of Na+-K+
ATPase in A1 adenosine receptor transgenic mice, this study
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showed that the A1 adenosine receptor regulates the expres-
sion of Na+-K+ ATPase in the choroid plexus [15]. Because
caﬀeine is commonly ingested chronically, it is important
to note that long-term exposure to adenosine receptor
antagonists like caﬀeine can have eﬀects that resemble the
acute eﬀects of adenosine receptor agonists, due likely to up-
regulation of adenosine receptors (A1 and A2A) and adaptive
changes leading to adenosine receptor sensitization [4]. The
results of the study by Han et al. [15] showed that the A1, but
not the A2A, adenosine receptor, was increased in the choroid
plexus of the caﬀeine-treated rats compared to the control
rats. It is important to note, however, that in another study,
the same level of caﬀeine administration to AD transgenic
mice did not aﬀect A1 or A2A receptor densities or expression
in either cerebral cortex or hippocampus [5]. Therefore, the
up-regulation of A1 adenosine receptors reported by Han et
al. [15] might be specific to the choroid plexus. Alternatively,
this A1 adenosine receptor up-regulation might be specific to
normal young adult rats. Furthermore, in their study, Han
et al. [15] noted a significant increase in the cerebral blood
flow of the caﬀeine-treated rats compared to the control
rats. This finding is contrary to the well-documented central
vasoconstrictive properties of caﬀeine that lead to a decrease
in cerebral blood flow in both animals and humans [18].
Given that cerebral blood flow aﬀects the production of CSF
[15], it would be interesting to investigate whether caﬀeine-
induced enhancement of CSF production also occurs in
other species or animal models.
Of major interest for the hypothesis presented here,
recent epidemiological and experimental studies suggest that
long-term caﬀeine consumption may be protective against
AD [4–7]. However, findings from cross-sectional studies
have been contradictory [19, 20]. Some studies indicated no
association between coﬀee drinking and AD, while others
found an inverse association between caﬀeine intake and AD
[19, 20]. Most of the longitudinal studies have consistently
found the cognitive benefits of long-term caﬀeine con-
sumption among the group of oldest people [19]. Several
studies have shown that long-term (years to decades) caﬀeine
consumption may result in improved cognitive function or
may protect against memory impairment observed in AD
and the ageing process [19]. In a 1989 paper by Lammi et al.
[21], low coﬀee consumption was reported to be associated
with mental disability after a 25-year follow-up of 716
Finnish men. In the Canadian Study of Health and Aging
(CSHA), daily coﬀee drinking decreased the risk of AD by
31% during a 5-year follow-up of subjects aged 65 years or
older [7]. A case-control study compared the daily intake of
caﬀeine in 54 AD patients with 54 nondemented matched
controls [6]. Patients with AD had an average daily caﬀeine
intake of 73.9 ± 97.9mg during the 20 years that preceded
diagnosis of AD, whereas the controls had an average daily
caﬀeine intake of 198.7± 135.7mg during the corresponding
20 years of their lifetimes [6]. The main finding of this study
was a significant inverse association between caﬀeine intake
and AD, and this association was independent of other habits
eventually related to caﬀeine consumption, medical disor-
ders that might influence caﬀeine intake and potential risk
factors for AD [6]. The Finland, Italy, and the Netherlands
Elderly prospective cohort study (the FINE study) evaluated
cognitive functioning and coﬀee consumption in 676 healthy
elderly men over a 10-year period [22]. An inverse and J-
shaped association was observed between the number of
cups of coﬀee consumed and cognitive decline, with the
least cognitive decline for three cups of coﬀee per day
[22]. This decline was 4.3 times smaller than the decline of
non-coﬀee drinkers [22]. The French Three City Study of
7017 individuals aged 65 years and older without dementia
examined the association between caﬀeine intake, cognitive
decline, and incident dementia [23]. While no relation
between caﬀeine intake and cognitive decline was found in
men, this prospective study found that women with high
rates of caﬀeine consumption (more than three cups per
day) had less decline in verbal retrieval, and to a lesser
extent in visuospatial memory over 4 years than women
consuming one cup or less [23]. The protective eﬀect of
caﬀeine was more notable in older versus younger women
[23]. No relationship was observed between caﬀeine intake
and the risk of dementia during 4 years of follow-up [23].
A Portuguese cohort study recently confirmed a protective
eﬀect of caﬀeine in women [24]. From a cohort of 648
subjects aged 65 and over, 531 participants were selected for
this study [24]. 309 participants completed the follow-up
evaluation (median follow-up: 48 months) [24]. This study
found that caﬀeine intake was associated with a lower risk
of cognitive decline in women, but not significantly in
men [24]. Cognitive decline was defined by a decrease of
at least 2 points in the score of the Mini-Mental State
Examination from baseline to the follow-up visit [24]. The
Cardiovascular Risk Factors, Aging and Dementia (CAIDE)
study investigated the associations of midlife coﬀee and/or
tea consumption to the development of dementia and
AD in late-life [20]. After following 1409 subjects for an
average of 21 years, this study found that coﬀee drinkers
at midlife had lower risk of dementia and AD later in
life compared with those drinking little or no coﬀee [20].
The lowest risk (65% decreased) was found in individuals
who drank 3–5 cups of coﬀee per day during their midlife
years [20]. Santos et al. [25] recently conducted a systematic
review and meta-analysis of published studies quantifying
the relation between caﬀeine intake and cognitive decline or
dementia. The authors found a trend towards a protective
eﬀect of caﬀeine, but the large methodological heterogeneity
across a still limited number of epidemiological studies
precluded robust and definite statements on this topic [25].
It should also be noted that there are inherent limitations
of observational epidemiological studies, in that causality
cannot be inferred from associations alone. A recent review
explored the relation between caﬀeine intake, diabetes,
cognition and dementia, focusing on type 2 diabetes [26].
The conclusion was that, although epidemiological studies
indicate that coﬀee/caﬀeine consumption is associated with
a decreased risk of type 2 diabetes and possibly also with a
decreased dementia risk, at present it is not certain that these
associations are causal [26].
As noted above, compromised function of the choroid
plexus and defective CSF production may be one mechanism
implicated in the pathogenesis of late-onset AD [8, 11].
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Given that long-term caﬀeine consumption may augment
CSF production [15], and given that increased CSF pro-
duction may improve the CSF turnover and clearance of
potentially toxic metabolites, such as Aβ, it seems reasonable
to speculate that long-term caﬀeine consumption could exert
protective eﬀects against AD, at least in part by facilitating
CSF secretion. To the best of our knowledge, no previous
study has suggested increased CSF production as a possible
mechanism underlying the inverse association between caf-
feine consumption and AD. However, there could be other
potential mechanisms of cognitive protection by caﬀeine.
Among them, the antioxidant properties of caﬀeine, its anti-
inflammatory capacities, its ability to block disruptions of
the blood-brain barrier, and its well-documented blockade
of adenosine A1 and A2A receptors have been proposed
to underlie its ability to protect against AD [5, 27]. Fur-
thermore, in a recent study, Arendash et al. [5] reported
that long-term caﬀeine administration that began in young
adulthood protected AD transgenic mice against otherwise
certain cognitive impairment in older age, while also limiting
their brain production of Aβ due to reduced expression of
both β-secretase and presenilin-1/γ secretase. The ability of
caﬀeine to reduce Aβ production was confirmed in neuronal
cell cultures from these same transgenic mice, wherein
concentration-dependent decreases in both Aβ (1–40) and
Aβ (1–42) were observed [5]. In another study, Arendash et
al. [28] found that aged, cognitively-impaired AD transgenic
mice given a moderate amount of daily caﬀeine exhibited a
restoration of working memory to the level of normal, aged
mice. In these same aged AD mice, which had pre-existing
and substantial Aβ burden, caﬀeine treatment reduced both
soluble and deposited (insoluble) brain Aβ levels [28]. Cao et
al. [27] recently reported that acute caﬀeine administration
to both young adult and aged AD transgenic mice rapidly
reduced Aβ levels in both brain interstitial-fluid and plasma
without aﬀecting Aβ elimination. A single treatment with
caﬀeine did not aﬀect the half-life of interstitial-fluid Aβ,
demonstrating that caﬀeine had aﬀected brain Aβ produc-
tion rather than its elimination [27]. The latter, however,
is not inconsistent with the idea that long-term caﬀeine
consumption may exert protective eﬀects against AD, at
least in part by increasing CSF production and clearance.
Indeed, chronic but not acute treatment of rats with caﬀeine
increased CSF production [15]. If our hypothesis were
correct, one would expect that enhanced CSF production by
chronic caﬀeine treatment should result in greater clearance
of Aβ from the brains of AD transgenic mice, resulting in
increased plasma Aβ levels. However, Cao et al. [27] reported
that both plasma and brain Aβ levels are reduced by acute
or chronic caﬀeine administration in several AD transgenic
lines and ages. Newly produced Aβ enters a dynamic
equilibrium between soluble and deposited Aβ in the brain,
with continual transport of soluble Aβ out of the brain and
into plasma [27]. As noted above, in their study in AD
transgenic mice, Arendash et al. [5] found that long-term
caﬀeine administration suppressed brain Aβ production by
reducing expression of both β-secretase and presenilin-1/γ
secretase. Acutely, such decreased Aβ production would
result in lower brain levels of soluble Aβ and consequently
lower plasma Aβ levels [27]. Continued caﬀeine suppression
of Aβ production and the resultant lower brain levels of
soluble Aβ would induce a flux of deposited (insoluble) Aβ
to the soluble form, which is cleared from brain into plasma
[27]. Consequently, plasma Aβ levels may be reduced or not
changed [27]. Therefore, despite a caﬀeine-induced increase
in CSF production resulting in enhanced clearance of Aβ
from the brain, chronic caﬀeine administration might result
in lower plasma Aβ levels due to its ability to decrease Aβ
production through suppression of both β-secretase and
presenilin-1/γ secretase.
3. Preclinical Evaluation of Hypothesis
The evaluation of preventive or disease-modifying eﬃcacy
is not easily accomplished in a clinical setting. Animal
models have therefore acquired a strong position in this field
of research based on the rapid development of symptoms
and/or pathology, availability of potentially large groups of
subjects, accessibility to early-stage CNS changes, and the
possibility of time-linked observations. Themajor shortcom-
ing of many preclinical trials scrutinizing disease-modifying
eﬃcacy is the lack of a wash-out period to prevent bias
from sustained symptomatic treatment eﬀects. Given the
acute (i.e., symptomatic) cognition enhancing eﬀects of caf-
feine, animal model studies assessing preventive or disease-
modifying treatment strategies based on caﬀeine or other
adenosine receptor antagonists, should include a wash-out
period prior to commencing cognitive and/or behavioural
analyses and correlating biochemical parameters. A preclin-
ical treatment schedule to assess disease-modification in
transgenic rodent models of dementia based on clinical with-
drawal designs has previously been proposed [29]. Treatment
starts prior to the first presentation of the symptoms and
continues past the time point where symptoms would occur
if untreated. Given caﬀeine has acute cognition enhancing
eﬀects that are partially based on its actions on arousal,
mood, and concentration, it is essential to include a wash-out
period to ensure picking up true disease-modifying eﬀects on
cognition (prevention of learning deficits) and not potential
acute cognition enhancing eﬀects of caﬀeine. The primary
goal would not be to mimic the physiological conditions of
daily caﬀeine intake in humans in amousemodel, but to have
a controlled experiment allowing appraisal of the hypothesis
that chronic caﬀeine intake would alter the progression of
AD on increased Aβ clearance via increased CSF production.
CSF production is not easily monitored in rodents, let
alone in mice. CSF formation rate can be measured by the
ventriculocisternal perfusion method, originally developed
in goats by Pappenheimer et al. [30], but downscaled
for application in rats and mice over the past decades.
Briefly, under stereotactic guidance, one (stainless steel)
cannula is introduced into the lateral cerebral ventricle,
while another is inserted into the cisterna magna. Artificial
CSF containing a (polysaccharide) dye, for example, Blue
Dextran 2000 [31] or tetramethylrhodamine isothionate-
dextran [32], is infused through the ventricular cannula
at a constant rate. CSF samples are collected via the
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cisterna magna at 20-min intervals allowing colorimetric
(for Blue Dextran 2000) or fluorometric detection (for
tetramethylrhodamine isothionate-dextran) of the dye as a
measure for CSF production rate (Vf in μL/min) based
on the following formula: Vf = Vi(Ci − Co)/Co with Vi
being the infusion rate of the perfusate, Ci the concentration
of the dye in the inflow fluid and Co the concentration
of the dye in the outflow fluid. Application of long-term
administration of caﬀeine in a mouse model for AD with
established face, construct, and predictive validity employing
a treatment strategy with a wash-out period to prevent bias
from known symptomatic treatment eﬀects [29] could allow
us to gain further insight in the mode of action underlying
the presumed disease-modifying eﬃcacy of caﬀeine or other
xanthine analogs. The measurement of CSF production
rate should be preceded by a test battery of behavioural
paradigms evaluating various learning and memory levels,
as well as BPSD-related alterations, known to be aﬀected in
the mouse model. CSF production needs to be linked to Aβ
clearance (Aβ CSF levels), as well as CNS plaque load and
CNS levels of diﬀerent (oligomeric) soluble and insoluble Aβ
species, preferably in addition to other AD- related patho-
physiological pathways including inflammation and oxi-
dative stress.
4. Conclusions
In conclusion, the hypothesis of the present paper is that
long-term caﬀeine consumption could exert protective ef-
fects against AD at least in part by facilitating CSF produc-
tion, turnover, and clearance. This obviously needs to be
confirmed by future research. If confirmed, then long-term
caﬀeine consumption could be protective against AD by lim-
iting production of Aβ, due to reduced expression of both
β-secretase and presenilin-1/γ secretase, and by facilitating
CSF production, with improved clearance of Aβ. It should be
stressed, however, that several other mechanisms also might
explain caﬀeine’s apparent protective eﬀect against AD.
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